Agape ATP Corporation (NASDAQ: ATPC) is a Malaysia-based holding company that supplies health and wellness products, supplements, and advisory services, alongside a smaller green energy segment. It is a micro-cap with a market capitalization of roughly $1.35 million, and it has almost no conventional sell-side research coverage. That makes the question of a "price target" unusually tricky — and it is why this article relies on publicly discussed technical objectives rather than an analyst consensus.
ATPC does not meet the bar for a meaningful analyst aggregate. Major data providers list no consensus price target, and the only tracked "rating" is a "Sell" from Weiss Ratings, which reflects a qualitative score rather than a numeric 12-month objective. There is no verifiable set of analyst targets from named firms to average.
Accordingly, the $1.60 figure is a fallback target drawn from identifiable public technical commentary. Multiple market observers have described the shares as consolidating between roughly $1.20–$1.22 support and $1.39–$1.40 resistance, and have noted that a break above that ceiling could open a move toward the $1.60 area and beyond. That is a realistic, publicly discussed objective — but it is a technical milestone, not an analyst forecast, and it should not be read as a consensus view.
The shares last traded around $1.35, near the top of a tight recent range. Reaching $1.60 would require a gain of about $0.25, or roughly 18.5%, a substantial move for a stock that frequently trades only a few thousand shares per session. The wide 52-week range — from $1.15 to $73.50 — largely reflects pre-split volatility and should be interpreted cautiously after the February 2026 reverse stock split.
Fundamentally, the company remains loss-making: revenue over the trailing twelve months is around $1.32 million against a net loss of roughly $1.2 million, and diluted EPS (earnings per share) is negative. At the same time, the balance sheet shows total cash of about $24.6 million, which is far larger than the market capitalization — an unusual setup that some observers see as providing a floor, though it is no guarantee of price appreciation.
The stock is rangebound, with support around $1.20–$1.22 and resistance near $1.39–$1.40. The $1.50 and $1.60 levels sit just above that ceiling as the next psychological and measured-move objectives. A decisive close above $1.40 would be the clearest signal that the $1.60 objective is in play, while a break below $1.20 would invalidate the near-term constructive setup.
Because no analyst targets exist, there is no published research horizon to cite. Technical objectives like $1.60 are typically viewed over weeks to months rather than a fixed 12-month window. Investors should monitor the next earnings report (estimated around late November 2026), any guidance or capital-raising announcements, trading volume, and whether the stock can close above $1.40 on higher-than-average activity. Changes in the cash position, new share issuances, and any reverse-split or listing-related developments also matter.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a thinly traded, volatile name like ATPC, such signals can help traders spot changing trends and manage positions more efficiently. Traders can use the tool to discover opportunities, monitor holdings, and stay ahead of shifts in momentum.
The $1.60 objective is a publicly discussed technical target, not an analyst consensus, because Agape ATP Corporation has no credible analyst price-target coverage. Reaching it would require roughly an 18.5% gain from the current price near $1.35. The setup rests on a potential breakout above $1.39–$1.40 resistance and an unusually cash-rich balance sheet, but it faces substantial obstacles in the form of recurring losses, micro-cap liquidity constraints, and a history of dilution and reverse splits. Whether the target is reached will depend heavily on volume, the next earnings report, and any corporate or capital-raising developments. No outcome is guaranteed, and this article makes no recommendation to buy or sell.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ATPC and LW have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ATPC and LW's prices will move in lockstep.
| Ticker / NAME | Correlation To ATPC | 1D Price Change % | ||
|---|---|---|---|---|
| ATPC | 100% | -5.08% | ||
| LW - ATPC | 20% Poorly correlated | -3.54% | ||
| DAR - ATPC | 17% Poorly correlated | -1.68% | ||
| LSF - ATPC | 14% Poorly correlated | -5.29% | ||
| RKDA - ATPC | 12% Poorly correlated | -1.00% | ||
| MAMA - ATPC | 12% Poorly correlated | +1.29% | ||
More | ||||
| Ticker / NAME | Correlation To ATPC | 1D Price Change % |
|---|---|---|
| ATPC | 100% | -5.08% |
| Food: Major Diversified industry (62 stocks) | 23% Poorly correlated | -0.36% |